Adalvo is delighted to announce that ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution is now available in the U.S. through our commercial partner, Azurity Pharmaceuticals.
Arynta offers a ready-to-use oral liquid option for patients with ADHD in children aged six and older, as well as adults, Arynta answers an unmet medical need for those who may have difficulty swallowing tablets or capsules, a common but often underdiagnosed challenge in treatment.
As a prodrug of amphetamine, lisdexamfetamine dimesylate has an established clinical profile with data supporting symptom control throughout the day in studied populations. Developed under the FDA’s 505(b)(2) category, Arynta will be available in four presentations.
Anil Okay, Adalvo's CEO comments, "We're proud to partner with Azurity to launch Arynta in the U.S. They have extensive experience bringing products to market in this therapeutic area and share our commitment to serving overlooked patients. It's also an important milestone for Adalvo — our first product in the US market."
This medication carries a boxed warning and has risks including abuse and dependence. Careful patient selection, monitoring and adherence to the prescribing information are essential.
To learn more about Adalvo’s US portfolio, contact one of the team today.
About Adalvo
Adalvo is Europe's fastest-growing B2B pharmaceutical company, providing 170+ partners with end-to-end capabilities spanning product conception to commercialization across 140+ countries. Headquartered in Malta with operations in 20+ countries, Adalvo's high-value portfolio includes over 30 differentiated technologies and a pipeline of ~60 projects due for market entry before 2030.
About Azurity
Azurity Pharmaceuticals is a privately held global pharmaceutical company dedicated to addressing the critical and often invisible crisis facing overlooked patients by offering innovative solutions to meet their specific, unmet needs, which often are ignored by the broader biopharmaceutical industry and not typically addressed by generic manufacturers. By reformulating, adapting, and developing new therapies that meet specialized patient needs, we are delivering treatment alternatives that solve issues impacting patients’ day-to-day lives. Azurity has a broad portfolio of more than 50 medicines across 10 therapeutic areas fueling its mission, powered by a next generation AI-driven sales and marketing tool called Azurity Commercial Excellence (ACE) to optimize customer engagement and improve product delivery to overlooked patients. For more information, visit www.azurity.com.